South Korea

The Ministry of Food and Drug Safety (MFDS), established as an independent agency in 2013, is the primary authority responsible for the regulation of pharmaceuticals, medical devices, diagnostics, and digital health products in South Korea. The principal governing legislation includes the Pharmaceutical Affairs Act, the Medical Devices Act (revised 2020), and the Digital Healthcare Promotion Act. The approval process generally requires pre-market submission of a product dossier, safety and efficacy data, and manufacturing quality documentation. Products are classified by risk level, with Class I devices subject to self-certification, Classes II through IV requiring MFDS review or third-party conformity assessment, and pharmaceuticals undergoing full clinical and non-clinical data review. The MFDS also oversees Good Manufacturing Practice (GMP) inspections, either through direct audit or recognition of inspections conducted by trusted foreign regulatory authorities.

Key submission requirements include the appointment of a local regulatory representative or Korean importer, who assumes legal responsibility for post-market obligations. South Korea accepts dossiers aligned with the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for pharmaceuticals, and follows the IMDRF framework for medical devices, including acceptance of ISO 13485 certification and technical documentation consistent with international standards. For in-vitro diagnostics, the MFDS applies a separate classification and review pathway under the Medical Devices Act. Notable recent reforms include the introduction of an innovative medical device designation track and a conditional approval pathway for breakthrough digital therapeutics and AI-based software as a medical device (SaMD), reflecting South Korea's ambition to be a regional leader in digital health innovation. The MFDS has also expanded mutual recognition and reliance arrangements with regulatory partners including the US FDA, EMA, and Health Canada to streamline review timelines for products already approved in reference jurisdictions.

Public procurement of health products in South Korea is primarily coordinated through the Ministry of Health and Welfare (MOHW) and executed via the Health Insurance Review and Assessment Service (HIRA) and the National Health Insurance Service (NHIS), which together govern reimbursement listing and pricing for pharmaceuticals and medical devices under the National Health Insurance (NHI) scheme. Manufacturers seeking public market access must first obtain MFDS marketing authorization, then apply for NHI listing through a pharmacoeconomic evaluation and price negotiation process managed by HIRA and the NHIS. The Drug Reimbursement Evaluation Committee and equivalent bodies for devices assess cost-effectiveness, clinical benefit, and budget impact before recommending listing. Centralized procurement for public hospitals and government institutions is handled through the Public Procurement Service (PPS), which conducts national framework tenders and manages the MAS (Multiple Award Schedule) system, allowing qualified suppliers to offer products directly to public sector buyers under pre-negotiated terms. There is no significant federal-versus-provincial split in procurement authority, as South Korea operates a largely centralized national health insurance and procurement system.

The private sector represents a substantial share of health product sales in South Korea, encompassing private hospitals, clinic networks, and retail pharmacy channels, where pricing is less regulated than in the NHI-listed segment. Multinational and domestic suppliers frequently operate dual-track strategies, pursuing NHI reimbursement for volume while maintaining premium private-channel pricing for non-listed innovations. South Korea is a high-income country and therefore not a primary recipient of donor-funded procurement programs such as those administered by UNICEF Supply Division, the Global Fund, USAID, or Gavi; however, South Korea itself contributes to and collaborates with these organizations through its development assistance programs. The government actively promotes local manufacturing through policies such as the Korea Bio-Health Industry Promotion Act and preferential consideration for domestically produced products in public tenders under certain conditions. The Korea Drug Pricing and Reimbursement system has also introduced innovation premium policies to incentivize domestic R&D and first-in-class product development, reinforcing industrial policy goals alongside public health objectives.